Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts

Figure 1 Analysis of data of marker Ki-67 from The Cancer Genome Atlas database and Genotype-Tissue Expression database. A: The difference of marker Ki-67 (MKI67) expression between 496 cases of prostate cancer (PCa) tissues and 152 cases of normal samples selected from The Cancer Genome Atlas (TCGA) database and Genotype-Tissue Expression (GTEx) database was calculated using Wilcoxon rank sum test; B: The data from TCGA database and GTEx database was used to verify the moderate ability of MKI67 expression to distinguish PCa tissues from normal samples by receiver operating characteristic (ROC) curve; C-G: The associations between MKI67 expression and clinicopathological characteristics were analyzed by Wilcoxon rank sum test using the data from TCGA; H: The association between MKI67 expression and progress-free interval (PFI) of PCa was analyzed by Kaplan-Meier method. The low- and high expression of MKI67 groups were divided by the median value of MKI67 expression using the data from TCGA database; I: The weak efficacy of MKI67 expression to predict the 1-, 2-, and 3-year PFI of PCa was proved through time-ROC curve using the data from TCGA database. PSA: Prostate-specific antigen; TPR: True positive rate; FPR: False positive rate; HR: Hazard ratio; AUC: Area under the curve; MKI67, marker Ki-67.